Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 30;69(6):308–316. doi: 10.1262/jrd.2023-023

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2023 Society for Reproduction and Development

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: https://creativecommons.org/licenses/by-nc-nd/4.0/)

PMC Copyright notice

Fig. 5. — Proportion of GH/Ki67-positive cells in the IL-side and AL-side MCL and the AL parenchyma. (A and D) Double immunohistochemistry for GH (green) and Ki67 (red) in the vehicle, GH treatment for 3 days (GHRH3d), continuous stress for 5 days (CS5d), and recovery for 3 days after CS for 5 days (CS5d RC3d) (A), and for TSH (green) and Ki67 (red) in the vehicle and 2-week propylthiouracil treatments (PTU) (D). DAPI (blue) was added to identify the nuclei. White arrowheads indicate GH/Ki67- (A) or TSH/Ki67-positive cells (D). (B, C and E) Proportion of GH/Ki67-positive cells from the DAPI-positive cells in each treatment. The cells were counted in the AL-side MCL (AL-MCL; B) and AL parenchyma (Parenchyma; C and E). AL, anterior lobe; IL, intermediate lobe; MCL, marginal cell layer; IL-MCL, IL side of the MCL. Scale bars: 20 μm (A and B). ** P < 0.01.